Bristol Area Library

New Search
Bibliography Information:
Collection: 7-day Books
Call Number: 338.7 Carreyou
Author: Carreyrou, John,
Title: Bad blood :
Remainder of title: secrets and lies in a Silicon Valley startup /
Summary, etc. note: "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--

International Standard Book Number: 9781524731656 (hardback)
Description conventions: rda
Authentication code: pcc
Geographic area code: n-us---
Classification number: HD9995.H423
Item number: U627 2018
Edition number: 23
Classification number: 338.7/681761
Source of number: bisacsh
Classification number: TEC059000
Classification number: BUS027000
Classification number: BUS025000
Relator term: author.
Statement of responsibility, etc.: John Carreyrou.
Edition statement: First Edition.
Place of publication: New York, NY
Name of publisher: Alfred A. Knopf
Date of publication: 2018
Projected publication date: 1810
: New York :
: Knopf,
: 2018.
Extent: x, 339 pages ;
Dimensions: 25 cm
Accompanying material: Includes bibliographical references & index.
: rdacontent
: text
: txt
: rdamedia
: unmediated
: n
: rdacarrier
: volume
: nc
Summary, etc. note: "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
: Provided by publisher.
: Provided by publisher.
Source of acquisition: B & T 08/27/2018
Purchase price: $ 27.95
Corporate name or jurisdiction name as entry element: Theranos (Firm)
General subdivision: History.
Source of heading or term: bisacsh
Source of heading or term: bisacsh
Source of heading or term: bisacsh
Subject: Hematologic equipment industry
Subject: Fraud
Subject: BUSINESS & ECONOMICS / Entrepreneurship.
Subject: BUSINESS & ECONOMICS / Finance.
Subject: TECHNOLOGY & ENGINEERING / Biomedical.
Geographic subdivision: United States.
Geographic subdivision: United States.
: Purchase
: 20180619
: 340568
: Amazon
: acquire
: 1 shelf copy
: policy default
: HAND CARRY X COPIES/CIP COPY/LP COPY/ANY COPIES NEEDED FOR CONGRESSIONAL LOAN; DO NOT DISCARD; PLS CONTACT/scar, x7717 2018-5-24
: rm13 2018-03-16
: hb09 2018-06-19 2 copies to LOAN
: rm13 2018-03-16 ONIX (telework)
: xm06 2018-03-20
: xm06 2018-03-20
: Anne; phone: 212-5724979; email: aachenbaum@penguinrandomhouse.com; bc: nlatimer@penguinrandomhouse.com

Bibliography Copy Information:

Barcode # Description Status Status Dt Due Back
49614 338.7 Carreyou checked in 2018-09-05 09:34:30